Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114256 · ClinicalTrials.gov registry record
FNA Tumor Sampling for CD137 Modulation: A Pilot Study
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 83
- Enrollment target
NCT01114256: Clinical Trial study, sponsored by Stanford University.
NCT01114256 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01114256 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand the biology of the body's immune response to monoclonal antibody therapy for cancer. Your health information will be used to identify your tissues. The tissue we obtain may be useful for research or education, resulting in new drugs, therapies or diagnostic procedures.
Interventions
- PROCEDURE FNA Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2010-03 |
| Est. Completion | 2016-01 |
Why NCT01114256 stopped before completion
NCT01114256 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 83 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which FNA Biopsy is the first listed.
NCT01114256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01114256 about?
NCT01114256 is a clinical study titled "FNA Tumor Sampling for CD137 Modulation: A Pilot Study". The purpose of this study is to better understand the biology of the body's immune response to monoclonal antibody therapy for cancer. Your health information will be used to identify your tissues. The tissue we obtain may be useful for research or education, resulting in new drugs, therapies or dia...
What is the current status of trial NCT01114256?
This trial is currently terminated. The enrollment target is 83 participants. The study started on 2010-03. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01114256?
The interventions under investigation include: FNA Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT01114256?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia